---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046839"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:08:52.519047+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics receives Nasdaq bid price deficiency notice; has until Sep 23, 2025 to cure

## Summary
- Nasdaq notified Prelude on March 27, 2025 that its common stock closed below $1.00 for 30 consecutive business days.
- Company has 180 calendar days, until September 23, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.
- If not compliant by Sep 23, Prelude may qualify for a second 180-day period if it meets other standards and intends a reverse stock split.
- No immediate impact on listing; stock continues trading on Nasdaq under symbol PRLD.

## SEC filing metadata
- accession: 0000950170-25-046839
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017025046839/0000950170-25-046839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017025046839/prld-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046839
- JSON: https://secwatch.observer/filing/0000950170-25-046839.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046839.txt

## Key facts
- Listing & Compliance Notices
  Prelude Therapeutics Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 27, 2025, Prelude Therapeutics Inc (the “Company”) received a letter (the “Bid Price Notice”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Bi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000095017025046839/0000950170-25-046839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.